SMARCA4 and cancer: As E-cadherin loss and the up-regulation of Vimentin are strongly associated with metastatic behavior and worse patient survival [43–45], the loss of BRG1 might affect cancer development by facilitating the loss of E-cadherin and the up-regulation of Vimentin in primary tumors as well as those with a metastatic phenotype.